Evidence Level:Resistant: C3 – Early Trials
New
Title:
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma
Excerpt:We identified 135 patients with mUC who received anti-PD1/L1 ICI….Patients with NLR ≥ 4 had a significant worse OS (8.2 months vs 17.7 months P = 0.0001).
DOI:https://doi.org/10.1101/2023.10.03.23296504